Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
289 participants
INTERVENTIONAL
2008-02-29
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin
NCT02053103
A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks
NCT00427401
A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients
NCT01298518
Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes
NCT01272804
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
NCT03985293
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
30 mg QD
PF-00734200 30 mg QD
30 mg QD
20 mg QD
PF-00734200 20 mg QD
20 mg QD
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-00734200 30 mg QD
30 mg QD
PF-00734200 20 mg QD
20 mg QD
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Chandler, Arizona, United States
Pfizer Investigational Site
Litchfield Park, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Artesia, California, United States
Pfizer Investigational Site
Cerritos, California, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Greenbrea, California, United States
Pfizer Investigational Site
Huntington Beach, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
National City, California, United States
Pfizer Investigational Site
Roseville, California, United States
Pfizer Investigational Site
Valley Village, California, United States
Pfizer Investigational Site
West Covina, California, United States
Pfizer Investigational Site
DeFuniak Springs, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
New Port Richey, Florida, United States
Pfizer Investigational Site
Ocala, Florida, United States
Pfizer Investigational Site
Pinecrest, Florida, United States
Pfizer Investigational Site
St. Petersburg, Florida, United States
Pfizer Investigational Site
Conyers, Georgia, United States
Pfizer Investigational Site
Idaho Falls, Idaho, United States
Pfizer Investigational Site
Indianapolis, Indiana, United States
Pfizer Investigational Site
Wichita, Kansas, United States
Pfizer Investigational Site
Lexington, Kentucky, United States
Pfizer Investigational Site
Madisonville, Kentucky, United States
Pfizer Investigational Site
Scarborough, Maine, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Oxon Hill, Maryland, United States
Pfizer Investigational Site
Ann Arbor, Michigan, United States
Pfizer Investigational Site
Bay City, Michigan, United States
Pfizer Investigational Site
Canton, Michigan, United States
Pfizer Investigational Site
Troy, Michigan, United States
Pfizer Investigational Site
Jackson, Mississippi, United States
Pfizer Investigational Site
Picayune, Mississippi, United States
Pfizer Investigational Site
City of Saint Peters, Missouri, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Elizabeth, New Jersey, United States
Pfizer Investigational Site
Trenton, New Jersey, United States
Pfizer Investigational Site
Albuquerque, New Mexico, United States
Pfizer Investigational Site
Syracuse, New York, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Marion, Ohio, United States
Pfizer Investigational Site
Eugene, Oregon, United States
Pfizer Investigational Site
Cumberland, Rhode Island, United States
Pfizer Investigational Site
Aiken, South Carolina, United States
Pfizer Investigational Site
Florence, South Carolina, United States
Pfizer Investigational Site
Kingsport, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
El Paso, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Hurst, Texas, United States
Pfizer Investigational Site
Odessa, Texas, United States
Pfizer Investigational Site
Pearland, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
Bennington, Vermont, United States
Pfizer Investigational Site
Ettrick, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Virginia Beach, Virginia, United States
Pfizer Investigational Site
Virginia Beach, Virginia, United States
Pfizer Investigational Site
Spokane, Washington, United States
Pfizer Investigational Site
Kenosha, Wisconsin, United States
Pfizer Investigational Site
Coquitlam, British Columbia, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Laval, Quebec, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Québec, Quebec, Canada
Pfizer Investigational Site
San Juan, , Puerto Rico
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A7941006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.